Preserved supervised synthesis

Tesamorelin synthesis · version 1

This URL preserves the exact reviewed public wording and source set for synthesis version 1.

Supervised synthesis

What do selected human studies report about Tesamorelin?

Manually reviewed August 19, 2026 · version 1

Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

A bounded review of two randomized placebo-controlled trials in adults living with HIV and abdominal fat accumulation.12

Bottom line from this bounded source set

The reviewed trials reported reductions in visceral adipose tissue, and the smaller trial also reported a modest reduction in liver fat. These studies do not establish long-term clinical outcomes or effects outside the studied HIV populations.12

Reviewed study record

Twenty-six-week visceral-fat trial

Design

A randomized, placebo-controlled trial assessed computed-tomography visceral adipose tissue and metabolic measures over 26 weeks.1

Population

The trial randomized 412 adults living with HIV who had abdominal fat accumulation during antiretroviral therapy; 86% were men.1

Outcomes reported

Visceral adipose tissue reportedly decreased by 15.2% with tesamorelin and increased by 5.0% with placebo. More participants receiving tesamorelin withdrew because of an adverse event, while the groups did not differ significantly in the reported glycemic measures.1

Limitations

The 26-week trial was limited to adults living with HIV and treatment-associated abdominal fat accumulation and did not establish longer-term clinical outcomes.1

Reviewed study record

Six-month visceral- and liver-fat trial

Design

A double-blind, randomized, placebo-controlled preliminary trial assessed visceral adipose tissue, liver fat, and metabolic measures over six months.2

Population

The single-center trial enrolled 50 antiretroviral-treated adults living with HIV and abdominal fat accumulation; 48 received study treatment.2

Outcomes reported

The reported treatment difference was -42 square centimeters for visceral adipose tissue and -2.9 percentage points for liver fat. The six-month glucose changes were not statistically significant.2

Limitations

The preliminary study was small, single-center, and six months long; the authors stated that further study was needed to determine clinical importance and long-term consequences.2

Reviewed source set

  1. PubMed · 18057338Metabolic effects of a growth hormone-releasing factor in patients with HIV ↗PubMed PMID 18057338 · EFetch XML reviewed 2026-08-19 · payload SHA-256 3e4af3676d797f96af2feabb38705dd17e6e1c1d9011cd116c22b449fb27151c
    No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa072375. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 25038357Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial ↗PubMed PMID 25038357 · EFetch XML reviewed 2026-08-19 · payload SHA-256 c2d1ad86512b5f64e032d05b54059a7cf624edb143d01fffb7b6ba757962ad1d
    No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1001/jama.2014.8334. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗